New drug cocktail aims to fight lung cancer in the brain
NCT ID NCT07361705
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether adding zorifertinib to the standard drug osimertinib is safe and helpful for people with advanced lung cancer that has spread to the membranes around the brain. About 42 participants will receive the combination pills daily. The main goal is to find the best dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zorifertinib and osimertinib combination therapy
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for patients with advanced lung cancer that has spread to the brain lining after standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 42 participants, focused on safety and dosing. The combination may not work better than existing treatments, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MENINGEAL PROGRESSION AFTER OSIMERTINIB TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital
RECRUITINGGuangzhou, Province, 518117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGHenan, Province, 450008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Cancer Hospital
RECRUITINGShanxi, Province, 030013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of China Medical University
RECRUITINGShengyang, City, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••